Sonoma Pharmaceuticals Inc (SNOA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sonoma Pharmaceuticals Inc (SNOA) has a cash flow conversion efficiency ratio of -0.098x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-649.00K) by net assets ($6.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Sonoma Pharmaceuticals Inc market cap and net worth for the company's overall valuation and market capitalisation.
Sonoma Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2005–2026)
This chart illustrates how Sonoma Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Sonoma Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sonoma Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Explore Sonoma Pharmaceuticals Inc cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tennant Minerals Ltd
AU:TMS
|
0.011x |
|
The North American Income Trust plc
LSE:NAIT
|
0.019x |
|
Reviva Pharmaceuticals Holdings Inc.
NASDAQ:RVPH
|
-0.389x |
|
NEPRA FOODS INC.
F:2P6
|
N/A |
|
Woodlandor Holdings Bhd
KLSE:7025
|
-0.017x |
|
TGS Esports Inc
V:TGS
|
0.391x |
|
GENINCODE PLC LS -01
F:9PL
|
N/A |
|
Riedel Resources Ltd
AU:RIE
|
-0.041x |
Annual Cash Flow Conversion Efficiency for Sonoma Pharmaceuticals Inc (2005–2026)
The table below shows the annual cash flow conversion efficiency of Sonoma Pharmaceuticals Inc from 2005 to 2026. View Sonoma Pharmaceuticals Inc stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-03-31 | $3.10 Million | $-3.93 Million | -1.271x | -6269.68% |
| 2025-03-31 | $4.41 Million | $-88.00K | -0.020x | +94.89% |
| 2024-03-31 | $6.14 Million | $-2.40 Million | -0.391x | +49.33% |
| 2023-03-31 | $7.98 Million | $-6.15 Million | -0.771x | -57.89% |
| 2022-03-31 | $8.70 Million | $-4.25 Million | -0.488x | +22.45% |
| 2021-03-31 | $5.36 Million | $-3.38 Million | -0.630x | +22.84% |
| 2020-03-31 | $5.62 Million | $-4.59 Million | -0.816x | +26.92% |
| 2019-03-31 | $10.49 Million | $-11.72 Million | -1.117x | -37.63% |
| 2018-03-31 | $15.33 Million | $-12.44 Million | -0.812x | -112.98% |
| 2017-03-31 | $21.43 Million | $-8.17 Million | -0.381x | +55.82% |
| 2016-03-31 | $10.14 Million | $-8.75 Million | -0.863x | -55.32% |
| 2015-03-31 | $12.05 Million | $-6.69 Million | -0.555x | -36.99% |
| 2014-03-31 | $12.06 Million | $-4.89 Million | -0.405x | -243.85% |
| 2013-03-31 | $4.08 Million | $1.15 Million | 0.282x | -93.93% |
| 2012-03-31 | $-868.00K | $-4.03 Million | 4.645x | +278.40% |
| 2011-03-31 | $1.70 Million | $-4.43 Million | -2.604x | -176.30% |
| 2010-03-31 | $7.04 Million | $-6.64 Million | -0.942x | +87.30% |
| 2009-03-31 | $2.27 Million | $-16.83 Million | -7.418x | -556.02% |
| 2008-03-31 | $15.43 Million | $-17.45 Million | -1.131x | +6.81% |
| 2007-03-31 | $14.90 Million | $-18.08 Million | -1.213x | +56.61% |
| 2006-03-31 | $7.34 Million | $-20.52 Million | -2.796x | +54.50% |
| 2005-03-31 | $2.20 Million | $-13.53 Million | -6.146x | -- |
About Sonoma Pharmaceuticals Inc
Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin f… Read more